Literature DB >> 6689425

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

P Carde, F R MacKintosh, S A Rosenberg.   

Abstract

A dose-response analysis of the results of MOPP chemotherapy in 132 patients with Hodgkin's disease was carried out. Complex statistical methods were utilized including 40 different dose-time variables and multivariate logistic analyses of 21 clinical variables, both simply and in stepwise regression. These covariates were not independent, and in stepwise regression analysis only B-symptoms and the mean three-cycle rate of drug delivery significantly influenced complete remission attainment. Two parameters, bone marrow involvement (negative) and lung involvement (positive), significantly influenced the duration of complete remission. Survival was influenced adversely by pleural involvement (effusion), advanced age, and B-symptoms. Analyses indicate that the dose of all three drugs (mustard, vincristine, and procarbazine), and the rate of drug delivery during the first three cycles are important in achieving maximal complete response rates, especially for patients with B-symptoms.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6689425     DOI: 10.1200/JCO.1983.1.2.146

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  19 in total

Review 1.  Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

Authors:  D J Dodwell; E S de Campos; J A Radford
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

Review 2.  Hodgkin's lymphoma. II: Treatment and delayed morbidity.

Authors:  P Carde
Journal:  BMJ       Date:  1992-07-18

Review 3.  Clinical pharmacokinetics-pharmacodynamics of anticancer drugs.

Authors:  W E Evans; M V Relling
Journal:  Clin Pharmacokinet       Date:  1989-06       Impact factor: 6.447

4.  Factors causing dose variability in drug administration.

Authors:  R Demicheli; A Jirillo; G Bonciarelli; F Lonardi; M Pradella; M Balli
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 5.  Current management of Hodgkin's disease.

Authors:  B C Behrens; R C Young; V T DeVita
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

Review 6.  Clinical aspects of Hodgkin's disease.

Authors:  G M Mead; J M Whitehouse
Journal:  BMJ       Date:  1988-12-17

7.  Compliance and cancer chemotherapy.

Authors:  J A Green
Journal:  Br Med J (Clin Res Ed)       Date:  1983-09-17

8.  High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.

Authors:  Susan O'Brien; Gary Schiller; John Lister; Lloyd Damon; Stuart Goldberg; Walter Aulitzky; Dina Ben-Yehuda; Wendy Stock; Steven Coutre; Dan Douer; Leonard T Heffner; Melissa Larson; Karen Seiter; Scott Smith; Sarit Assouline; Philip Kuriakose; Lori Maness; Arnon Nagler; Jacob Rowe; Markus Schaich; Ofer Shpilberg; Karen Yee; Guenter Schmieder; Jeffrey A Silverman; Deborah Thomas; Steven R Deitcher; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2012-11-19       Impact factor: 44.544

Review 9.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

Review 10.  Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity.

Authors:  W E Evans
Journal:  Blut       Date:  1988-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.